Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
NCT06033820
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B-cell Lymphoma Recurrent
Diffuse Large B Cell Lymphoma Refractory
Interventions
DRUG:
ZR2-ICE
Sponsor
RenJi Hospital